Colorectal Cancer: Screening, Staging, and Systemic Therapy

Colorectal cancer (CRC) encompasses malignancies arising from the colon and rectum, representing the third most common cancer and second leading cause of cancer death in the United States. [KEY_CONCEPT] CRC primarily develops through the adenoma-carcinoma sequence, where benign adenomatous polyps progress to invasive adenocarcinoma over 10-15 years.

Epidemiology:

• Annual incidence: ~150,000 new cases in the United States
• Median age at diagnosis: 68 years
• 5-year survival rate: 65% overall, varies significantly by stage
• Rising incidence in adults <50 years has prompted updated screening guidelines [6]

Risk Factors:

• Modifiable: Diet high in red/processed meat, smoking, alcohol, obesity, sedentary lifestyle
• Non-modifiable: Age >50, male sex, African American ethnicity, inflammatory bowel disease
• Hereditary syndromes: Lynch syndrome (hereditary nonpolyposis colorectal cancer), familial adenomatous polyposis

[HIGH_YIELD] Molecular Subtypes:

• Microsatellite stable (MSS): ~85% of cases, associated with chromosomal instability
• Microsatellite instability-high (MSI-H): ~15% of cases, deficient mismatch repair (dMMR)
• Consensus molecular subtypes (CMS): CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), CMS4 (mesenchymal)

Pathophysiology: CRC develops through accumulation of genetic alterations including APC mutations (early), KRAS mutations (intermediate), and TP53 mutations (late). The mismatch repair system maintains genomic stability, and deficiency leads to MSI-H tumors with increased mutational burden and enhanced immunogenicity [6].

Current Screening Recommendations: [HIGH_YIELD] The American Cancer Society and U.S. Preventive Services Task Force now recommend beginning CRC screening at age 45 for average-risk individuals, reduced from the previous age of 50 due to rising incidence in younger populations [6].

Screening Methods:

High-Risk Screening:

• Family history: Begin screening 10 years before youngest affected relative's age or age 40, whichever is earlier
• Lynch syndrome: Annual colonoscopy starting age 20-25
• Inflammatory bowel disease: Begin 8-10 years after diagnosis

[CLINICAL_PEARL] Circulating tumor DNA (ctDNA) is emerging as a biomarker for minimal residual disease detection and may guide adjuvant therapy decisions in stage II-III disease [6].

Quality Metrics:

• Adenoma detection rate: Target >25% in men, >15% in women
• Cecal intubation rate: Target >95%
• Withdrawal time: Minimum 6 minutes

TNM Staging System (AJCC 8th Edition):

Staging Algorithm:

Primary Tumor (T): Tis → Carcinoma in situ T1 → Invades submucosa T2 → Invades muscularis propria T3 → Invades subserosa/pericolic tissue T4a → Penetrates visceral peritoneum T4b → Invades adjacent organs

Regional Lymph Nodes (N): N0 → No regional lymph nodes N1 → 1-3 regional lymph nodes N1a → 1 regional lymph node N1b → 2-3 regional lymph nodes N1c → Tumor deposits without nodes N2 → 4+ regional lymph nodes N2a → 4-6 regional lymph nodes N2b → 7+ regional lymph nodes

Distant Metastasis (M): M0 → No distant metastasis M1a → 1 organ/site M1b → 2+ organs/sites M1c → Peritoneal surface

Stage Groupings:

[KEY_CONCEPT] Prognostic Factors:

• Pathologic stage: Most important predictor
• Histologic grade: Well, moderate, poor differentiation
• Lymphovascular invasion: Associated with increased recurrence
• Perineural invasion: Poor prognostic factor
• Microsatellite instability status: MSI-H associated with better prognosis but resistance to 5-FU
• Molecular markers: KRAS, NRAS, BRAF, HER2 mutations affect treatment selection

[HIGH_YIELD] Minimum lymph node harvest: At least 12 lymph nodes should be examined for adequate staging.

First-Line Therapy for Metastatic CRC:

Chemotherapy Backbone Options:

• FOLFOX: 5-FU/leucovorin + oxaliplatin
• FOLFIRI: 5-FU/leucovorin + irinotecan
• CAPOX: Capecitabine + oxaliplatin

Targeted Therapy Selection:

Immunotherapy in CRC: [HIGH_YIELD] MSI-H/dMMR tumors (~4% of metastatic CRC) show exceptional response to immune checkpoint inhibitors:

• Pembrolizumab: FDA-approved first-line for MSI-H/dMMR mCRC
• Nivolumab ± ipilimumab: Alternative option
• Response rates: 40-60% vs <5% in MSS tumors

Treatment Algorithm:

Metastatic CRC Treatment Decision Tree:

MSI-H/dMMR? → YES → Pembrolizumab monotherapy ↓ NO RAS Wild-Type? → YES → FOLFOX/FOLFIRI + anti-EGFR ↓ NO BRAF Mutated? → YES → FOLFOXIRI + bevacizumab ↓ NO Patient Fitness? ├─ Fit → FOLFOX/FOLFIRI + bevacizumab └─ Frail → Capecitabine + bevacizumab

Resistance Mechanisms & Sequencing:

• Acquired KRAS mutations: Develop resistance to anti-EGFR therapy
• Bevacizumab: Can be continued beyond progression (TML study)
• Regorafenib/trifluridine-tipiracil: Third-line options for refractory disease

[CLINICAL_PEARL] Liquid biopsy can detect circulating tumor DNA and emerging resistance mutations, potentially guiding treatment switches before radiographic progression.

Adjuvant Therapy Recommendations:

Stage II Colon Cancer:

• Standard approach: Surgery alone for most patients
• Consider adjuvant therapy for high-risk features:
  • T4 tumors
  • <12 lymph nodes examined
  • Poorly differentiated histology
  • Lymphovascular/perineural invasion
  • Bowel obstruction/perforation

[KEY_CONCEPT] MSI-H Stage II: Adjuvant 5-FU may be detrimental - avoid single-agent fluoropyrimidine therapy

Stage III Colon Cancer:

• Standard: FOLFOX or CAPOX for 3-6 months
• Duration: IDEA collaboration showed 3 months non-inferior to 6 months for low-risk T1-3, N1 disease
• Oxaliplatin contraindications: Consider 5-FU/capecitabine alone

Rectal Cancer Neoadjuvant Approaches:

Total Neoadjuvant Therapy (TNT):

TNT Approach: Induction chemotherapy (3-4 months) ↓ Chemoradiotherapy (6 weeks) ↓ Surgery (8-12 weeks later) ↓ Adjuvant therapy completion

[HIGH_YIELD] Watch-and-Wait Strategy: For rectal cancer patients achieving complete clinical response after neoadjuvant therapy, active surveillance may be considered as an alternative to surgery.

Emerging Biomarkers:

• Circulating tumor DNA (ctDNA): May identify patients who benefit from adjuvant therapy in stage II disease [6]
• Immune profiling: Immunoscore being validated as prognostic marker
• Microsatellite instability: Guides both prognosis and treatment selection

[CLINICAL_PEARL] Oxaliplatin neuropathy is dose-limiting and often irreversible. Consider stopping oxaliplatin after 3 months in low-risk stage III patients to minimize toxicity while maintaining efficacy.

Treatment-Related Complications:

Surgical Complications:

• Anastomotic leak: 2-15% incidence, higher in rectal cancer
• Wound infection: 15-20% incidence
• Bowel obstruction: 10-15% long-term risk
• Sexual/urinary dysfunction: Common after rectal surgery

Chemotherapy Toxicities:

Long-term Survivorship Issues:

Surveillance Protocol:

• History/Physical: Every 3-6 months for 2 years, then every 6 months
• CEA levels: Every 3-6 months for 2 years (if elevated preoperatively)
• CT chest/abdomen/pelvis: Every 6-12 months for 3 years
• Colonoscopy: 1 year postoperatively, then every 3-5 years

[HIGH_YIELD] Recurrence Patterns:

• Liver: Most common site (50-70% of metastases)
• Lungs: Second most common (20-30%)
• Peritoneum: Associated with poor prognosis
• Local recurrence: More common with rectal cancer

Quality of Life Considerations:

• Ostomy management: ~20% of CRC patients have permanent ostomy
• Fertility preservation: Consider sperm/egg banking before treatment
• Cognitive effects: "Chemo brain" reported in 20-30% of patients
• Financial toxicity: Significant cost burden of targeted therapies

[CLINICAL_PEARL] Oligometastatic disease (1-3 metastatic lesions) may benefit from metastasectomy or stereotactic radiotherapy, potentially achieving long-term disease-free survival in selected patients.

Secondary Prevention:

• Lifestyle modifications: Regular exercise, healthy diet, smoking cessation
• Aspirin: May reduce recurrence risk (ongoing clinical trials)
• Vitamin D: Adequate levels associated with improved outcomes